氨溴索静脉滴注联合布地奈德雾化吸入对新生儿肺炎患儿炎症反应、血气分析指标及症状消退时间的影响

Effect of Ambroxol Intravenous Drip Combined with Budesonide Aerosol Inhalation on Inflammatory Reaction,Blood Gas Analysis Indicator and Symptom Regression Time in Children with Neonatal Pneumonia

目的探讨氨溴索静脉滴注联合布地奈德雾化吸入在新生儿肺炎(NP)患儿中的治疗效果.方法选取2020年6月—2022年6月我院收治的70例NP患儿,按随机数字表法分为两组,各35例.对照组给予氨溴索静脉滴注治疗,观察组在对照组基础上加用布地奈德雾化吸入,持续治疗1周.对比两组临床疗效、炎症反应、症状消退时间、血气分析指标及不良反应发生情况.结果观察组治疗总有效率94.29%,高于对照组的77.14%,差异有统计学意义(P<0.05).治疗前,两组炎症因子、血气分析指标水平比较,组间差异无统计学意义(P>0.05);治疗后,观察组白细胞介素-6水平(88.65±6.99)ng/L、降钙素原水平(33.13±4.32)mg/L、C反应蛋白水平(4.19±0.81)mg/L、二氧化碳分压水平(36.54±4.11)mmHg均低于对照组的(97.14±8.23)ng/L、(39.61±4.50)mg/L、(5.24±1.10)mg/L、(43.37±4.28)mmHg,动脉氧分压(94.52±5.75)mmHg高于对照组的(88.38±6.40)mmHg,咳嗽消退时间(4.37±0.66)d、咳痰消退时间(4.80±0.88)d、气促消退时间(3.90±0.84)d、肺部啰音消退时间(4.10±0.84)d、发热消退时间(4.73±0.95)d均短于对照组的(5.10±0.42)d、(6.01±1.13)d、(4.87±0.73)d、(5.16±0.77)d、(6.12±0.69)d,组间差异有统计学意义(P<0.05).两组不良反应发生率比较,差异无统计学意义(P>0.05).结论氨溴索静脉滴注联合布地奈德雾化吸入能增强NP治疗效果,改善血气分析指标与炎症反应水平,促进症状消退,且不会增加不良反应.

Objective To investigate the therapeutic effect of ambroxol intravenous drip combined with budesonide aerosol inhalation in children with neonatal pneumonia(NP).Methods 70 children with NP admitted to our hospital from June 2020 to June 2022 were selected and divided into two groups according to random number table method,with 35 cases in each group.The control group was treated with ambroxol intravenous drip,and the observation group was treated with budesonide aerosol inhalation on the basis of the control group,with both interventions for 1 week.The clinical efficacy,inflammatory reaction,symptom resolution time,blood gas analysis indicator and occurrence of adverse reactions of the two groups were compared.Results The total effective rate of treatment of the observation group was 94.29%,higher than 77.14%of the control group,with statistically significant difference(P<0.05).Before treatment,there were no significant differences between the two groups in inflammatory factor and blood gas analysis indicator levels(P>0.05);after treatment,interleukin-6 level(88.65±6.99)ng/L,procalcitonin level(33.13±4.32)mg/L,C-reactive protein level(4.19±0.81)mg/L and partial pressure of carbon dioxide level(36.54±4.11)mmHg in the observation group were lower than(97.14±8.23)ng/L,(39.61±4.50)mg/L,(5.24±1.10)mg/L and(43.37±4.28)mmHg in the control group,the arterial partial pressure of oxygen(94.52±5.75)mmHg was higher than(88.38±6.40)mmHg of the control group,the cough resolution time(4.37±0.66)d,expectoration resolution time(4.80±0.88)d,shortness of breath resolution time(3.90±0.84)d,lung rale resolution time(4.10±0.84)d and fever resolution time(4.73±0.95)d in the observation group were shorter than(5.10±0.42)d,(6.01±1.13)d,(4.87±0.73)d,(5.16±0.77)d and(6.12±0.69)d in the control group,with statistically significant differences between the groups(P<0.05).There was no significant difference in the incidence of adverse reactions between groups(P>0.05).Conclusion Ambroxol intravenous drip combined with budesonide aerosol inhalation can enhance the therapeutic effect of NP,improve blood gas analysis indicators and inflammatory reaction level,promote the resolution of symptoms,and do not increase adverse reactions.